Next generation sequencing, an Early HTA in form of a conceptual framework for the histological/cytological diagnostics practice for advanced non-small cell lung cancer

Lung cancer is the second most frequent cancer site in both males and females. It remains the leading cause of cancer incidence and mortality in Norway. The most frequent classification of lung cancer is advanced Non-small cell lung cancer (NSCLC), accounting for 80-85 percent. Contributing to the most deaths, advanced NSCLC has a 5-year relative survival hovering around 20 percent. In the context of NSCLC, with a high incidence and mortality rate, it is important to evaluate the emerging innovations from personalised medicine within diagnostic and treatments practice which might lead to increased relative survival among the patient population.
The main objective of this study is to conduct an early health technology assessment (HTA). Central to this early HTA is the development of the conceptual framework which present two conceptual models that encompasses the practice of the histological/cytological genome testing for advanced NSCLC patients. These genome tests are performed either through next generation sequencing (NGS) by Roche diagnostics, NGS by ThermoFisher as a comparator, or single genome testing through Idylla as the standard diagnostic genome testing practice. The framework will also include parameter recommendations to include in the conceptual models.


  • Nei
  • Begrunnelse: Prosjektet bruker ikke sensitive data


  • Nei


NSD - Ikke behov

Prosjektet bruker ikke sensistive data

REK - Ikke behov

Prosjektet bruker ikke sensistive data


Knut Reidar Wangen

Ansvarlig enhet

Avdeling for helseledelse og helseøkonomi


  • Martin Grøvdal Thoresen (UiO)


  • Studentprosjekt – Bachelor-, master- eller spesialistoppgave

Helsefaglig forskning

  • Ja


  • Ikke besvart


  • Start: januar 2019
  • Slutt: juni 2019
Logg inn for å redigere prosjekter